Septicemic plague is a life-threatening infection caused by the gram-negative coccobacillus Yersinia pestis, characterized by bloodstream infection without localizing signs such as buboes or pneumonia. [1-2] It carries the highest case fatality rate among plague forms — 38% even with treatment in published case series, and is nearly universally fatal if untreated. [1][3] A delay of more than 24 hours in initiating antibiotics and antishock therapy can be fatal. [4]
1. History
- Exposure history is critical: flea bites, contact with rodents/prairie dogs/rabbits, handling infected animal carcasses, domestic cat scratches/bites, travel to endemic areas (southwestern US, Madagascar, Democratic Republic of Congo, parts of Asia) [1][5]
- Onset 2–8 days after exposure with abrupt high fever, rigors, chills, malaise, headache [1][6]
- Prominent GI symptoms: abdominal pain (reported in nearly half of cases), nausea, vomiting, diarrhea — a distinguishing feature that often misleads clinicians [1][6]
- No bubo or lymphadenopathy in primary septicemic plague (this is what makes it diagnostically treacherous) [2]
- Rapid progression to prostration, altered mental status, shock [6-7]
- Occupational history: hunters, veterinarians, hikers, campers in endemic regions [5]
2. Alarm Features
- Hypotension, tachycardia, tachypnea — signs of gram-negative septic shock [6]
- Petechiae, purpura, ecchymoses — herald DIC [7]
- Acral gangrene (digits, nose) — the historical "Black Death" finding, but occurs late and is not useful for early diagnosis [7]
- Altered mental status, obtundation
- Hemoptysis or cough developing in a septicemic patient → secondary pneumonic plague (now person-to-person transmissible) [1][7]
- Nuchal rigidity → secondary plague meningitis [1]
- Any young patient (<30 years) with undifferentiated gram-negative sepsis in an endemic area — deaths from septicemic plague disproportionately affect younger patients who may not receive empiric coverage [6]
3. Medications
First-line treatment (CDC 2021 guidelines): [1]
- Gentamicin 5 mg/kg IV/IM q24h PLUS ciprofloxacin 400 mg IV q8h (or levofloxacin 750 mg IV q24h)
- Streptomycin 1 g IV/IM q12h (if available) is the historical gold standard [2][8]
Alternatives: [1]
- Ciprofloxacin or levofloxacin monotherapy (fluoroquinolones)
- Moxifloxacin 400 mg IV/PO q24h
- Doxycycline 200 mg IV loading, then 100 mg IV q12h (listed as alternative for septicemic plague based on animal data; less robust evidence than for bubonic) [1]
- Chloramphenicol 12.5–25 mg/kg IV q6h (max 1 g/dose) — add if meningitis suspected [1]
Contraindicated/Ineffective
- Penicillins — 75% case fatality rate; not effective against plague [9]
- Beta-lactams/cephalosporins — not recommended [2]
Duration: 10–14 days total; extend if ongoing fever or concerning signs [1]
Cautions: Monitor aminoglycoside levels (nephrotoxicity, ototoxicity); adjust for renal function [1]
4. Diet
- NPO if hemodynamically unstable or intubated
- Aggressive IV fluid resuscitation as part of septic shock management
- No specific dietary triggers or long-term dietary considerations
5. Review of Systems
- Constitutional: fever, chills, rigors, malaise, prostration
- GI: abdominal pain, nausea, vomiting, diarrhea (frequently prominent) [1][6]
- Respiratory: cough, dyspnea, hemoptysis (suggests secondary pneumonic plague) [1]
- Neurologic: headache, confusion, meningismus (suggests meningeal spread) [1]
- Skin: petechiae, purpura, ecchymoses, acral cyanosis/gangrene [7]
- MSK: myalgias, arthralgias
6. Collateral History and Family History
- Household contacts and co-exposures — critical for public health notification and post-exposure prophylaxis [1]
- Recent dead rodents or animals observed near residence
- Other household members or close contacts with febrile illness
- Family history is not a significant contributor (non-hereditary disease)
- Social context: poverty, rural living, occupational exposure to wildlife [5]
7. Risk Factors
- Residence in or travel to endemic areas: southwestern US (New Mexico, Arizona, Colorado), Madagascar, DRC, parts of Central/East Asia [1][10]
- Age >40 years — higher risk of developing septicemic (vs. bubonic) plague [6]
- Flea exposure, contact with rodents, prairie dogs, rabbits, domestic cats [1][8]
- Hunters, trappers, veterinarians [5]
- Immunocompromised status (limited data but concerning) [1]
- Bioterrorism exposure — Y. pestis is a CDC Category A bioterrorism agent [3][7]
8. Differential Diagnosis
The absence of localizing signs makes septicemic plague a great mimicker:
- Other gram-negative sepsis (meningococcemia, E. coli, Klebsiella) — most common misdiagnosis [6]
- Meningococcemia — similar purpura fulminans presentation
- Rocky Mountain Spotted Fever — endemic overlap in southwestern US; petechial rash, tick exposure
- Tularemia — similar exposure history (rabbits, ticks); ulceroglandular or typhoidal forms
- Anthrax (inhalational or septicemic) — bioterrorism differential
- Severe malaria — if travel to co-endemic tropical regions
- Toxic shock syndrome — rapid-onset sepsis with hypotension
- Acute mesenteric ischemia — if abdominal pain is the dominant symptom
- Hantavirus pulmonary syndrome — rodent exposure overlap in southwestern US
9. Past Medical History
- Prior plague exposure or vaccination (historical; no current vaccine available)
- Immunosuppression (HIV, transplant, chemotherapy)
- Chronic kidney disease (affects aminoglycoside dosing)
- Hepatic disease (affects chloramphenicol metabolism)
- Splenectomy (increased susceptibility to encapsulated/gram-negative organisms)
10. Physical Exam
Vital signs
- tachycardia, tachypnea, hypotension[6]
Focused exam
- Skin: petechiae, purpura, ecchymoses, acral cyanosis/gangrene (late finding) [7]
- Lymph nodes: notably absent lymphadenopathy in primary septicemic plague (distinguishes from bubonic) [2]
- Abdomen: diffuse tenderness, guarding (GI symptoms are common and misleading) [6]
- Lungs: crackles, signs of consolidation if secondary pneumonic plague developing
- Neuro: altered mental status, meningismus if meningeal involvement [1]
- Extremities: digital ischemia, mottling
11. Lab Studies
- Blood cultures (×2 before antibiotics) — usually positive; Y. pestis grows on standard media in 24–48 hours [2][7]
- ⚠️ Automated systems may misidentify Y. pestis — alert the lab if plague is suspected [2][7]
- Y. pestis is a BSL-3 pathogen — label specimens as high risk [2]
- CBC: leukocytosis with marked left shift (bandemia) [6]
- CMP: assess renal/hepatic function (guides antibiotic dosing)
- Coagulation studies: PT/INR, fibrinogen, D-dimer — evaluate for DIC
- Lactate: marker of tissue hypoperfusion
- Procalcitonin: may support bacterial sepsis diagnosis
- Gram stain of blood: gram-negative coccobacilli; bipolar "safety pin" staining with Wright-Giemsa or Wayson stain [2][7]
- PCR (pla and caf1 genes): available at reference labs; remains positive even after antibiotics started [5]
- Serology (F1 antibody titers): useful for retrospective confirmation; seroconversion at 1–2 weeks [2]
12. Imaging
- Chest X-ray: obtain to evaluate for secondary pneumonic plague (bilateral infiltrates, consolidation) [1]
- CT abdomen: consider if abdominal pain is prominent to rule out surgical pathology
- No pathognomonic imaging findings for primary septicemic plague
- Imaging is primarily used to exclude other diagnoses and detect complications
13. Special Tests
- F1 antigen rapid diagnostic test (dipstick): point-of-care test with ~89–94% sensitivity on-site; better specificity under laboratory conditions [11]
- Direct fluorescent antibody (DFA) testing on blood smear if available [7]
- Specific bacteriophage lysis test: confirmatory at reference laboratories [2]
- PCR-lateral flow assay: emerging rapid molecular diagnostic [12]
- Notify state/local health department and CDC immediately upon clinical suspicion — plague is a nationally notifiable disease and potential bioterrorism agent [1][7]
14. ECG
- No plague-specific ECG findings
- Obtain ECG to evaluate for:
- Tachyarrhythmias secondary to sepsis
- Signs of myocardial dysfunction/myocarditis
- QTc prolongation (baseline before fluoroquinolone administration)
- Electrolyte-related changes (hyperkalemia in renal failure/DIC)
15. Assessment
Clinical summary: Septicemic plague presents as undifferentiated gram-negative sepsis with fever, GI symptoms, and rapid hemodynamic deterioration — without the diagnostic clue of a bubo. [1-2][6] It accounts for 10–25% of plague cases and is frequently associated with diagnostic delays. [2] The key to diagnosis is maintaining a high index of suspicion based on epidemiologic exposure in endemic areas.
Severity stratification
- Untreated: nearly 100% fatal [1]
- Treated with effective antibiotics: case fatality 20–38% depending on the series [3][9]
- Delay >24 hours in antibiotic initiation dramatically increases mortality [4]
Complications: DIC, ARDS, secondary pneumonic plague (now transmissible), meningitis, multiorgan failure, acral gangrene [1][7]
16. Treatment Plan
Initial stabilization
- Standard sepsis bundle: IV access, aggressive crystalloid resuscitation, vasopressors as needed
- Droplet precautions immediately (upgrade to airborne if pneumonic plague suspected) [7]
- Draw blood cultures, then start antibiotics within minutes — do not wait for confirmatory testing
Antimicrobial regimen (adults) per CDC 2021: [1]
- Transition IV → PO when clinically improving [1]
- Duration: 10–14 days [1]
- Monitor aminoglycoside levels and renal function [1]
- Post-exposure prophylaxis for close contacts: doxycycline 100 mg PO BID or ciprofloxacin 500 mg PO BID × 7 days [1]
17. Disposition
- All patients with septicemic plague require ICU admission — this is a critical illness with high mortality [4][6]
- Droplet isolation (standard + droplet precautions); upgrade to airborne if pneumonic plague suspected [7]
- There is no role for observation or outpatient management in septicemic plague
- Mandatory public health notification: contact state/local health department and CDC immediately [1]
- Infectious disease consultation — urgent
- Consider critical care, pulmonology if ARDS develops
18. Follow Up / Return Precautions
- Survivors require completion of full 10–14 day antibiotic course [1]
- Monitor for late complications: plague meningitis (can appear 9–14 days after onset, especially in younger patients), abscess formation, acral gangrene requiring surgical management [1][7]
- Renal function monitoring post-aminoglycoside therapy
- Audiometry if prolonged aminoglycoside use
- Close contacts should complete prophylaxis course and be monitored for 7 days for fever or symptoms [1]
- Return immediately for: recurrent fever, new cough/hemoptysis, confusion/stiff neck, worsening skin lesions, digit color changes
- Report to public health for epidemiologic investigation and flea/rodent control measures in the exposure area [1][13]
References
1. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
2. Plague. — Prentice MB, Rahalison L. Lancet. 2007.
3. Antimicrobial Treatment of Human Plague: A Systematic Review of the Literature on Individual Cases, 1937-2019. — Nelson CA, Fleck-Derderian S, Cooley KM, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020.
4. Plague: Clinics, Diagnosis and Treatment. — Nikiforov VV, Gao H, Zhou L, Anisimov A. Advances in Experimental Medicine and Biology. 2016.
5. Rapid Diagnostic Tests for Plague. — Jullien S, Dissanayake HA, Chaplin M. The Cochrane Database of Systematic Reviews. 2020.
6. Septicemic Plague in New Mexico. — Hull HF, Montes JM, Mann JM. The Journal of Infectious Diseases. 1987.
7. Plague as a Biological Weapon: Medical and Public Health Management. — Inglesby TV, Dennis DT, Henderson DA, et al. The Journal of the American Medical Association. 2000.
8. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
9. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. — Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020.
10. Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague. — Randremanana RV, Raberahona M, Bourner J, et al. The New England Journal of Medicine. 2025.
11. Performance of Diagnostic Procedures for Bubonic Plague in Endemic Settings in Madagascar: A Prospective Test Accuracy Sub-Study Within the IMASOY Trial. — Raberahona M, Rajerison M, Edwards T, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2026.
12. Development of a PCR-lateral Flow Assay for Rapid Detection of Yersinia Pestis, the Causative Agent of Plague. — Singh R, Pal V, Kumar M, Tripathi NK, Goel AK. Acta Tropica. 2021.
13. Yersinia Pestis: The Natural History of Plague. — Barbieri R, Signoli M, Chevé D, et al. Clinical Microbiology Reviews. 2020.